ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. We developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise. ZELTIQ has received regulatory clearance from the U.S. Food and Drug Administration to market CoolSculpting in the United States for the selective reduction of fat around the flanks and the abdomen area. ZELTIQ has also received regulatory approval or is otherwise free to market CoolSculpting in 55 international markets.
investor.coolsculpting.com/
financials.morningstar.com/...ent/is.html?t=ZLTQ&ops=clear
www.4-traders.com/ZELTIQ-AESTHETICS-INC-9229653/financials/
investor.coolsculpting.com/
financials.morningstar.com/...ent/is.html?t=ZLTQ&ops=clear
www.4-traders.com/ZELTIQ-AESTHETICS-INC-9229653/financials/
